Andrew Schwab Sells 400,000 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

Key Points

• Director Andrew Schwab sold 400,000 CAMP4 Therapeutics shares at an average price of $4.04, generating $1.616 million and reducing his position by 16.44% to 2.03 million shares.
• CAMP shares fell 4.6% to $3.96, while the company reported a quarterly loss of $0.58 per share—well below analysts’ expected loss of $0.24—on revenue of $1.78 million.
• Despite weak earnings and the insider sale, analysts remain generally positive: seven rate the stock Buy, one Hold, and one Sell, producing a “Moderate Buy” consensus and an average price target of $9.56.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 400,000 shares of the firm's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the transaction, the director owned 2,033,270 shares in the company, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CAMP4 Therapeutics Stock Down 4.6%

Shares of CAMP4 Therapeutics stock traded down $0.19 during trading hours on Monday, reaching $3.96. 190,269 shares of the company's stock were exchanged, compared to its average volume of 187,803. The business has a fifty day moving average of $4.13 and a two-hundred day moving average of $4.36. The company has a market capitalization of $248.49 million, a P/E ratio of -1.71 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, research analysts predict that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $36,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at $78,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics during the 4th quarter worth about $115,000.

Analysts Set New Price Targets

CAMP has been the topic of several recent research reports. Weiss Ratings raised shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Zacks Research raised shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a "buy" rating in a research report on Wednesday, June 10th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. raised CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source